Free Trial

Zimmer Biomet (ZBH) Competitors

Zimmer Biomet logo
$99.44 +1.07 (+1.09%)
Closing price 10/15/2025 03:59 PM Eastern
Extended Trading
$98.99 -0.45 (-0.45%)
As of 10/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZBH vs. PEN, SYK, GEHC, PHG, SNN, SOLV, STVN, IRTC, BLCO, and GKOS

Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Penumbra (PEN), Stryker (SYK), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), and Glaukos (GKOS). These companies are all part of the "medical" sector.

Zimmer Biomet vs. Its Competitors

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Penumbra has a net margin of 11.54% compared to Zimmer Biomet's net margin of 10.51%. Zimmer Biomet's return on equity of 12.76% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Zimmer Biomet10.51% 12.76% 7.21%
Penumbra 11.54%11.55%8.76%

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by company insiders. Comparatively, 4.2% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zimmer Biomet presently has a consensus price target of $111.94, suggesting a potential upside of 12.57%. Penumbra has a consensus price target of $302.81, suggesting a potential upside of 19.83%. Given Penumbra's stronger consensus rating and higher possible upside, analysts plainly believe Penumbra is more favorable than Zimmer Biomet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
2 Sell rating(s)
8 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45
Penumbra
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.89

In the previous week, Zimmer Biomet had 9 more articles in the media than Penumbra. MarketBeat recorded 20 mentions for Zimmer Biomet and 11 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.89 beat Penumbra's score of 0.52 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
12 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Penumbra
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zimmer Biomet has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.83B2.51$903.70M$4.1124.20
Penumbra$1.19B8.25$14.01M$3.7667.21

Summary

Zimmer Biomet and Penumbra tied by winning 8 of the 16 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZBH vs. The Competition

MetricZimmer BiometMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$19.49B$10.68B$6.11B$21.91B
Dividend Yield1.01%1.91%5.73%3.62%
P/E Ratio24.2020.5185.3630.12
Price / Sales2.5126.68601.9667.12
Price / Cash7.4625.0737.4624.26
Price / Book1.593.4812.424.70
Net Income$903.70M$208.83M$3.32B$1.01B
7 Day Performance2.12%-0.59%0.57%0.49%
1 Month Performance0.36%3.16%10.52%1.61%
1 Year Performance-5.70%-6.35%72.99%13.30%

Zimmer Biomet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZBH
Zimmer Biomet
4.769 of 5 stars
$99.44
+1.1%
$111.94
+12.6%
-4.9%$19.49B$7.83B24.2017,000Analyst Forecast
PEN
Penumbra
4.5133 of 5 stars
$255.35
-0.3%
$302.93
+18.6%
+22.3%$9.96B$1.28B67.914,500Analyst Forecast
SYK
Stryker
4.9572 of 5 stars
$365.99
-1.2%
$430.33
+17.6%
+3.0%$139.92B$22.60B48.4853,000Positive News
Analyst Forecast
GEHC
GE HealthCare Technologies
4.0146 of 5 stars
$76.41
-0.2%
$86.89
+13.7%
-19.3%$34.89B$19.97B15.6653,000Positive News
Analyst Forecast
PHG
Koninklijke Philips
3.618 of 5 stars
$28.04
+0.1%
N/A-13.4%$27.00B$17.86B147.5866,678
SNN
Smith & Nephew SNATS
3.516 of 5 stars
$35.94
-1.0%
$36.00
+0.2%
+24.1%$15.65B$5.81B16.6417,349Analyst Forecast
SOLV
Solventum
2.88 of 5 stars
$73.88
-0.2%
$84.60
+14.5%
+2.7%$12.81B$8.25B34.2022,000Positive News
STVN
Stevanato Group
1.5013 of 5 stars
€24.57
-5.4%
N/A+29.8%€7.44B€1.15B45.505,521
IRTC
iRhythm Technologies
1.4907 of 5 stars
$175.74
+0.1%
$172.17
-2.0%
+192.2%$5.65B$591.84M-59.982,000Analyst Forecast
BLCO
Bausch + Lomb
1.5837 of 5 stars
$14.87
-2.2%
$15.60
+4.9%
-27.7%$5.26B$4.79B-19.0613,500
GKOS
Glaukos
4.4265 of 5 stars
$86.64
-0.9%
$122.00
+40.8%
-33.1%$4.97B$432.95M-52.51780Analyst Forecast

Related Companies and Tools


This page (NYSE:ZBH) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners